Anthropologist and author Eben Kirksey discusses his interest in somatic and hereditary human genome editing, particularly the impact on patients and practitioners, the history of CCR5 gene editing, and recalls his exceptional reporting in China in the wake of the CRISPR babies scandal, all of which is included in his riveting book “The Mutant Project” (2020).

The architect of base editing and prime editing, Harvard University chemist David R. Liu, recalls the genesis of the technology and discusses exciting preclinical results and potential future applications. {Sponsored by Pegasus Books}

In this podcast, Mendelspod host Theral Timpson interviews Kevin Davies about his latest book, "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing". {Episode Sponsored by Mendelspod}

A conversation with Dame Kay Davies, University of Oxford geneticist and co-chair of the just-published international commission report on Hereditary Human Genome Editing (HHGE), which lays out a roadmap for if, when, and how we should proceed with embryo editing for couples with severe genetic diseases.

A discussion with Luciano Marraffini, the Rockefeller University microbiologist who has made several fundamental contributions in the brief history of CRISPR biology and genome editing.

Canadian law professor Bartha Knoppers (McGill University) talks about her long-standing interests in genetics, bioethics, human rights and her latest role studying the clinical implementation of genome editing.

A towering figure in genomics for three decades, George Church (Harvard Medical School) discusses pigs, mammoths, organoids, CRISPR babies, and why M stands for multiplexing.

The recently retired founding CEO of Sangamo Therapeutics, Edward Lanphier, shares stories from two decades at the helm of the first biotech company to develop and take genome editing, using zinc finger nucleases, into the clinic.

One of the pioneers of gene editing, biochemist Dana Carroll (University of Utah), reflects on the crucial early years developing zinc finger nucleases and the prospects for genome editing.

The director of “Human Nature” takes us behind the camera to discuss the making of the new documentary film that superbly captures the story of CRISPR.

While postdocs in David Liu’s lab at Harvard University, Alexis Komor (UCSD) and Nicole Gaudelli (Beam Therapeutics) developed a pair of CRISPR-based molecular machines known as base editors, capable of engineering precise single-base substitutions with enormous basic research and therapeutic implications.

In a French bistro in New York City, Emmanuelle Charpentier (Founding Director, Max Planck Unit for the Science of Pathogens, Berlin) discusses with Kevin Davies her nomadic career, the high points in her CRISPR journey, and previews her future plans.

Sylvain Moineau (Laval University, Quebec) surveys the impact of two decades’ research in phage microbiology on the CRISPR gene editing revolution.

GuidePost: A conversation with CRISPR pioneer Francisco Mojica is the first episode in a new podcast series from Mary Ann Liebert, Inc., publishers of The CRISPR Journal. Episode 1 is brought to you by MilliporeSigma CRISPR - Innovative reagents you can trust. In this episode Kevin Davis, Executive Editor of The CRISPR Journal, interviews Francisco Mojica from the University of Alicante.

In episode #2 of GuidePost, Kevin Davies (Executive Editor, The CRISPR Journal) travels to Lithuania to meet Virginijus Šikšnys, one of the central figures in the development of CRISPR gene editing, at his lab at the Institute of Biotechnology, Vilnius University. Siksnys is an expert in DNA-protein interactions, and in 2011-12, made critical contributions in transferring the Cas9 enzyme into E. coli and characterizing the mechanism by which it cuts DNA.

In episode #4 of GuidePost, Jacob Sherkow (New York Law School) – one of the leading academic authorities on biotech patent law – explains the twists and turns of the ongoing CRISPR patent dispute.

In episode 5 of GuidePost Podcast Series Neal Gutterson, Chief Technology Officer of Dow-Dupont’s agricultural division Corteva, discusses the exciting potential of gene editing/CRISPR to spur new crop strains and circumvent the contentious debate around GMOs.

In episode #6 of GuidePost, Kevin Holden, Head of Synthetic Biology at Synthego Corporation, discusses the company’s Silicon Valley culture, growth, and its approach to providing new gene editing products for the CRISPR community.

Kevin Esvelt (MIT Media Lab) discusses his interest in gene drives and other gene editing approaches to combat tick-borne diseases and malaria.

The CRISPR Journal Executive Editor Kevin Davis interviews Editor-In-Chief Rodolphe Barrangou. This episode of GUIDEpost is brought to you by Synthego, who's vision is to turn biology into an information science with the ultimate goal of dramatically extending the healthy human lifespan by providing genome engineering solutions. Learn more at www.synthego.com.